Recent

% | $
Quotes you view appear here for quick access.

Enzo Biochem Inc. Message Board

surfer_bj 15 posts  |  Last Activity: May 25, 2016 2:04 PM Member since: Sep 28, 2001
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Cap 25.1 M vs Cash $21.6 M and phase 3 to begin this year. Stock should move up to correct market cap and their positive pipeline of drugs...

    Sentiment: Buy

  • surfer_bj surfer_bj May 11, 2016 2:51 PM Flag

    Just saw upgrades on Etrade today. 2 Analyst have a Buy Rating for ORPH at $30.
    Buy 05/11/16 Jonathan Aschoff, Brean Capital
    TipRanks Star
    Ranking
    Price Target
    for OHRP
    $30.00
    Analyst Average

    Buy
    12/10/15
    Elemer Piros
    Roth Capital
    TipRanks Star
    Ranking

    Price Target
    for OHRP
    $30.00

    Sentiment: Buy

  • Petx is already proving they have the ability to create major drugs in a short time. There's going to be a day as there portfolio grows, a major company will make a bid for Petx. Expecting a great future for PETX.

    Sentiment: Strong Buy

  • Veterinary medicine concern Aratana Pharmaceuticals signed a significant collaboration deal with a unit of Eli Lilly and looks poised for more upside.

    Sentiment: Strong Buy

  • surfer_bj surfer_bj Apr 27, 2016 1:25 PM Flag

    There were no rumors of a major partnership in the foreseeable future. So that makes it a buy on the news. PETX has more future drugs soon to be announced this year. So this makes the stock is under valued and being manipulated.

    Sentiment: Strong Buy

  • Eli Lilly Bulks Up Animal-Drug Business --

    8:59 ET - Lavish spending on pets has helped create a big business at drug maker Eli Lilly (LLY), and is spurring the company to pursue deals. Animal drugs accounted for more than 15% of Lilly's 1Q revenue, compared with less than 10% a few years ago. "We like this business," Lilly CEO John Lechleiter tells the WSJ. "We're going to keep that business and I think it represents another good pillar of growth." The January 2015 acquisition of Novartis' animal-health business for $5.4B made Lilly the third-largest animal-health company by sales, and it has since pursued more modest deals. Yesterday Lilly licensed the rights to a drug treating osteoarthritis in dogs from Aratana Therapeutics (PETX). Lilly is paying $45M upfront plus potential additional payments of up to $83M if the drug meets certain development and sales goals.

    Sentiment: Strong Buy

  • surfer_bj surfer_bj Apr 26, 2016 1:42 PM Flag

    Glad to see one sour short is out. Guess great major partner news and $45 Mil new cash plus huge future income from a major company makes a short have negative words towards PETX.

    PETX is moving in the right direction growing it's portfolio into a major business. They are just getting started adding new drugs. Expect tosee a lot more major news coming for PETX.

    Sentiment: Strong Buy

  • Reply to

    Denial is costly

    by satenomaq Apr 21, 2016 1:13 PM
    surfer_bj surfer_bj Apr 21, 2016 2:32 PM Flag

    Today May 20, 2016 puts $4.00 and $5.00....is Telling you something that will become reality soon...

    Sentiment: Buy

  • Reply to

    As Volume Drops – Share Price Drops

    by skydiver1013 Apr 21, 2016 12:16 PM
    surfer_bj surfer_bj Apr 21, 2016 1:04 PM Flag

    This type of thinking would make every future blockbuster drug showing a positive phase II become a depressed stock. I can name you hundreds of companies with NO approved products past and presence that gain in share price (some Big Time) because of a future positive blockbuster drug in their future....

    .Think you are having a moment of doubt you want everyone to believe, for your own advantage.

    Sentiment: Buy

  • RPRX will discuss plans ending the phase II trial with FDA and to start a phase III trial.
    Repros believes Prollex "represents a significant advantage over GnRH agonists and antagonists in the treatment of uterine fibroids."

    Here is the statics on how Proellex could become a blockbuster drug for RPRX.

    ***About 30 percent of all women get fibroids by age 35 and almost 80 percent of women will have fibroids by age 50.*** Black women are more likely to have them, and to get them at a younger age. The cause of fibroids is unknown. About 40 percent of fibroids will grow during pregnancy, usually within the first three months.

    Most women do not want surgery and wait it out many years to see if they shrink later in life. But in the meantime, there is a need for a better way to control the problems they cause. I myself know along with many other family members and other women. This is so common and Proellex may just become a drug of choice compared to a few other treatments that are not full proof or have their side effects.

  • surfer_bj surfer_bj Apr 19, 2016 8:51 PM Flag

    I looked at the trading volume back to 1993, recent volume appears to be the highest volume RPRX has ever experienced. Usually a 1 or 2 day high volumes occur. Continued high volume shows that RPRX stock price is undervalued given the positive Proellex news on such a drug that covers a huge population of women. Add that with news that their other drug may be back on track going forward.

    Sentiment: Buy

  • Reply to

    Baker Bros

    by jay_scott27 Apr 5, 2016 9:26 AM
    surfer_bj surfer_bj Apr 6, 2016 4:24 PM Flag

    Makes no sense what you just said? If they where purchasing shares last year before the failed drug news, means they where paying top dollar for those shares. If the results were a complete failure, there would be no FDA involved with the go ahead with phase III trial. That trial showed a very positive side of the drug that corrects vision and more....

    How did many companies with positive drug sales end up where they are today holding millions/billions of Outstanding shares. Yes they used shares for research. Their shares climbed as new drugs became reality.
    If you have a good drug and plan your share price will outdo any dilution.
    Many of the promoters do overstate future price, but than again many understate future price of a stock.

    Sentiment: Buy

  • surfer_bj surfer_bj Mar 29, 2016 7:10 PM Flag

    OHRP BUY Target $30.000/Jonathan Aschoff Brean Capital Posted on E-Trade As of 03/28/2016
    Note Before News....Leaves me to believe he knew the deadline for news was about to come anytime and seen the hints and comments from management on positive vision results.

    Sentiment: Buy

  • Reply to

    Dr. Slakter's confidence

    by robertbriskin Mar 29, 2016 1:52 PM
    surfer_bj surfer_bj Mar 29, 2016 4:56 PM Flag

    Since investors always find out news after top management, there are a few companies who give investors a hint by continued purchase of company shares when they have knowledge of the drug performance or other positive information..

    I remember a company shares that were brought down to $1's and $2's by shorts and negative articles, by you know who (starts with a F), just before phase III was completed. It was a major drug for a small company. In the last months CEO continued to buy boatloads of shares till the time of the FDA approval was announced. Stock went crazy for days and a major company bought them out within that year.....

    Just shows you Dr. Slakter knows what he's doing, and anyone saying making negative remarks, may just be showing how dense and blind they can be. Phase II showing Positive Vision is not negative outcome like many wanted you to believe.

    The first of two randomized, double-masked, placebo-controlled trials will include approximately 165 centers in the United States and Canada and is expected to enroll approximately 650 treatment nave subjects with wet AMD. The primary efficacy endpoint of the clinical trial is the change in visual function at nine months.

    Sentiment: Buy

  • Reply to

    phase 3 and partnership

    by ajake397 Feb 28, 2016 4:37 PM
    surfer_bj surfer_bj Feb 29, 2016 9:54 PM Flag

    I am sure there is much work for Ohrp. to prepare in order to insure that everything is correct and in line for FDA to sign off. There will be news and I am sure management is making sure they are going over everything with a fine tooth comb. They may ask for more information or delay time as they tend to do.

    Just knowing how much vision improvement in patients is a huge positive for going forward in the Phase 3. Finding the right partner with the right deal can take time.

    Sentiment: Buy

ENZ
6.18-0.070(-1.12%)May 27 4:02 PMEDT